Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state

(2016) Naif Alhawiti et al.   THROMBOSIS RESEARCH

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

(2014) P. Valent et al.   BLOOD

Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion

(2014) Abdullah Katgı et al.   CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia

(2014) D. Rea et al.   HAEMATOLOGICA

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study

(2013) Luciano Levato et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

(2013) Z. Racil et al.   HAEMATOLOGICA

Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis

(2013) F Gerald R Fowkes et al.   LANCET

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abl Family Kinases Regulate Endothelial Barrier Function In Vitro and in Mice

(2013) Elizabeth M. Chislock et al.   PLoS One

Nilotinib-Associated Vascular Events

(2012) Alfonso Quintás-Cardama et al.   Clinical Lymphoma Myeloma & Leukemia

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

(2011) Karl J. Aichberger et al.   AMERICAN JOURNAL OF HEMATOLOGY

Nilotinib treatment-associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia

(2011) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Severe Peripheral Arterial Disease During Nilotinib Therapy

(2011) P. Le Coutre et al.   JNCI-Journal of the National Cancer Institute

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

(2008) Alfonso Quintás-Cardama et al.   Future Oncology

New therapeutic approaches and prognostic factors in chronic myeloid leukemia

(2008) Giuseppe Saglio et al.   LEUKEMIA & LYMPHOMA